| Original language | English (US) |
|---|---|
| Article number | 1901511 |
| Journal | European Respiratory Journal |
| Volume | 54 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 1 2019 |
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
The importance of real-life research in respiratory medicine : Manifesto of the Respiratory Effectiveness Group. / the Respiratory Effectiveness Group Collaborators.
In: European Respiratory Journal, Vol. 54, No. 3, 1901511, 01.09.2019.Research output: Contribution to journal › Editorial › peer-review
}
TY - JOUR
T1 - The importance of real-life research in respiratory medicine
T2 - Manifesto of the Respiratory Effectiveness Group
AU - the Respiratory Effectiveness Group Collaborators
AU - Roche, Nicolas
AU - Anzueto, Antonio
AU - Anticevich, Sinthia Bosnic
AU - Kaplan, Alan
AU - Miravitlles, Marc
AU - Ryan, Dermot
AU - Soriano, Joan B.
AU - Usmani, Omar
AU - Papadopoulos, Nikolaos G.
AU - Canonica, G. Walter
AU - Agache, Ioanna
AU - Barnes, Peter
AU - Bateman, Eric
AU - Behr, Jürgen
AU - Bjermer, Leif
AU - Blakey, John
AU - Bouros, Demosthenes
AU - Bousquet, Jean
AU - Brown, Kevin
AU - Brusselle, Guy
AU - Calderon, Moises
AU - Campbell, Jon
AU - Cardell, Lars Olaf
AU - Castro-Rodriguez, Jose A.
AU - Chaudhuri, Nazia
AU - Chavannes, Niels
AU - Corte, Tamera
AU - Costello, Richard
AU - Cottin, Vincent
AU - Custovic, Adnan
AU - Dandurand, Ronald
AU - Diamant, Zuzana
AU - Demoly, Pascal
AU - Ducharme, Francine
AU - Feleszko, Wojciech
AU - Fitzgerald, Mark
AU - Fokkens, Wytske
AU - Freeman, Daryl
AU - Gaga, Mina
AU - Geiser, Thomas
AU - Glaspole, Ian
AU - Gouder, Caroline
AU - Haughney, John
AU - Heaney, Liam
AU - Hedlin, Gunilla
AU - Hellings, Peter
AU - Hoe, Teoh Oon
AU - Israel, Elliot
AU - Jartti, Tuomas
AU - Jones, Mark
N1 - Funding Information: This document has been Endorsed by the International Primary Care Respiratory Group and the World Allergy Organization. The authors wish to thank the Respiratory Effectiveness Group Team (Michael Walker, CEO and Supporter Liaison, Naomi Launders, Senior Scientific Researcher and Sarah Lucas, Researcher) and Oversight Committee (Keith Allan, Trevor Lambert and Nick May). Funding Information: Conflict of interest: N. Roche reports grants and personal fees from Boehringer Ingelheim, Novartis and Pfizer, personal fees from Teva, GSK, AstraZeneca, Chiesi, Mundipharma, Sanofi, Sandoz, 3M, Zambon and Trudell, outside the submitted work. A. Anzueto reports personal fees for consultancy from GlaxoSmithKline, AstraZeneca and Boehringer Ingelheim, outside the submitted work. S. Bosnic Anticevich reports personal fees for advisory board work from TEVA, personal fees for consultancy from GSK and MEDA, grants from TEVA, personal fees for lectures from TEVA, GSK and AstraZeneca, personal fees for manuscript preparation from MEDA, personal fees for educational activities from GSK, outside the submitted work. A. Kaplan reports grants and personal fees from AstraZeneca, Boehringer Ingelheim and Pfizer, personal fees from Covis, GSK, Sanofi, Merck Frosst, Novartis, Purdue, Teva, Trudel, Novo Nordisk and Griffols, during the conduct of the study. M. Miravitlles reports personal fees for lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, Zambon, CSL Behring, Grifols and Novartis, personal fees for consultancy from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, TEVA, pH Pharma, Novartis and Grifols, grants from GlaxoSmithKline and Grifols, outside the submitted work. D. Ryan reports personal fees for advisory board work from GSK, BI and Novartis, personal fees for lectures and advisory board work from AZ, personal fees for lectures and meeting attendance from MEDA, outside the submitted work; and was previous president of REG, current vice president of REG and consultant strategic medical adviser, Optimum Patient Care. J.B. Soriano participated in speaking activities, advisory committees and consultancies during the period 2014–2019 sponsored by: Almirall, AstraZeneca, Boehringer Ingelheim, Chest, Chiesi, ERS, GEBRO, Grifols, GSK, Linde, Lipopharma, Mundipharma, Novartis, Pfizer, RiRL, Rovi, Sandoz, SEPAR and Takeda. O. Usmani reports grants and personal fees from AstraZeneca, Boehringer Ingelheim and Chiesi, grants from GlaxoSmithKline and Edmond Pharma, personal fees from Aerocrine, Napp, Mundipharma, Sandoz, Takeda, Zentiva and Cipla, outside the submitted work. N. Papadopoulos reports personal fees for advisory board work and lectures from Novartis, Nutricia, HAL, MENARINI/FAES FARMA and MYLAN/MEDA, personal fees for lectures from SANOFI, BIOMAY, MSD, ASIT BIOTECH and Boehringer Ingelheim, personal fees for advisory board work from AstraZeneca and GSK, grants from Gerolymatos International SA and Capricare, outside the submitted work. G.W. Canonica has nothing to disclose.
PY - 2019/9/1
Y1 - 2019/9/1
UR - http://www.scopus.com/inward/record.url?scp=85072390937&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072390937&partnerID=8YFLogxK
U2 - 10.1183/13993003.01511-2019
DO - 10.1183/13993003.01511-2019
M3 - Editorial
C2 - 31537655
AN - SCOPUS:85072390937
SN - 0903-1936
VL - 54
JO - The European respiratory journal
JF - The European respiratory journal
IS - 3
M1 - 1901511
ER -